Duo Oncology

Duo Oncology is a pharmaceutical startup focused on developing tumor-responsive nanomedicines to treat difficult-to-target cancers. Their proprietary platform utilizes particles inspired by DNA self-assembly that are roughly 10-30nm in size, which is significantly smaller than many competing nanomedicines. These ultrasmall particles are designed to penetrate dense, obstructive stromal tissue surrounding tumors, shielding their drug payloads from rapid systemic clearance. Once in the tumor microenvironment, the particles utilize a three-trigger sensitive bond system to release a combination of two anti-cancer therapies directly at the target site, enhancing localized delivery and efficacy while potentially reducing systemic toxicity.

This technology is intended to address significant unmet needs in oncology, particularly for patients with stroma-rich and intractable tumors. The company’s lead product, DUO-207, is a gemcitabine/paclitaxel nanomedicine that has received FDA Orphan Drug Designation for pancreatic cancer and is being prepared for clinical trials. By combining multiple therapeutic agents into a single, precision-delivered nanomedicine, Duo Oncology aims to provide superior outcomes compared to standard regimens. The company, which is based in Pittsburgh, leverages the expertise of clinical oncologists and pharmaceutical scientists to advance its pipeline through preclinical and regulatory milestones, supported by grants from the National Cancer Institute and private investment.